39%
per independent review using
RECIST v1.1 (12/31 [efficacy
population]; 95% CI: 22%, 58%)1
1.4months
median time to
response (95% CI: 1.3,
2.8 months)2
>3years
50% of patients had a DOR
of 39.7+ months (95% CI:
6.5 months to not reached)1
HALF OF RESPONDERS WERE STILL RESPONDING AFTER 3 YEARS1
HALF OF RESPONDERS WERE STILL RESPONDING AFTER 3 YEARS1
AMPECT=Advanced Malignant PEComa Trial; DOR=duration of response; PEComa=perivascular epithelioid cell tumor; RECIST=Response Evaluation Criteria in Solid Tumors.
References: 1. Wagner AJ, Ravi V, Riedel RF, et al. Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update. J Clin Oncol. Published online March 1, 2024. doi.org/10.1200/JCO.23.02266 2. Wagner AJ, Ravi V, Riedel RF, et al. nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors. J Clin Oncol. 2021;39(33):3660-3670. doi:10.1200/JCO.21.01728